Articles related to DRUG SAFETY & INTERACTIONS

Vitamin D supplementation requires careful consideration of drug interactions, particularly with commonly prescribed medications that affect CYP3A4 metabolism or calcium homeostasis.

Analysis of more than 16.6 million pregnancies shows no significant increase in adverse outcomes for women maintaining methylphenidate or atomoxetine treatment during pregnancy.

Zinc supplementation requires careful consideration of medication schedules, with specific timing gaps needed for common prescriptions to maintain therapeutic efficacy.

Monthly hepatic monitoring becomes mandatory for the first three months of Veozah therapy, marking a significant shift in safety protocols for menopausal vasomotor symptom management.

Multiple post-licensure studies have failed to demonstrate ticagrelor’s superiority over clopidogrel, prompting leading cardiologists to call for guideline reappraisal.

N-nitroso-duloxetine poses increased cancer risk at higher concentrations and extended exposure periods, prompting FDA-mandated strict limits on nitrosamine levels in medications.